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A B S T R A C T
Peroxisomes are eukaryotic organelles that function in numerous metabolic pathways and defects in peroxisome
function can cause serious developmental brain disorders such as adrenoleukodystrophy (ALD). Peroxisomal
membrane proteins (PMPs) play a crucial role in regulating peroxisome function. Therefore, PMP homeostasis is
vital for peroxisome function. Recently, we established that certain PMPs are degraded by the Ubiquitin
Proteasome System yet little is known about how faulty/non-functional PMPs undergo quality control. Here we
have investigated the degradation of Pxa1p, a fatty acid transporter in the yeast Saccharomyces cerevisiae. Pxa1p
is a homologue of the human protein ALDP and mutations in ALDP result in the severe disorder ALD. By in-
troducing two corresponding ALDP mutations into Pxa1p (Pxa1MUT), fused to mGFP, we show that Pxa1MUT-
mGFP is rapidly degraded from peroxisomes in a proteasome-dependent manner, while wild type Pxa1-mGFP
remains relatively stable. Furthermore, we identify a role for the ubiquitin ligase Ufd4p in Pxa1MUT-mGFP de-
gradation. Finally, we establish that inhibiting Pxa1MUT-mGFP degradation results in a partial rescue of Pxa1p
activity in cells. Together, our data demonstrate that faulty PMPs can undergo proteasome-dependent quality
control. Furthermore, our observations may provide new insights into the role of ALDP degradation in ALD.
1. Introduction
Peroxisomes are eukaryotic organelles that encompass a protein-
rich matrix bound by a single membrane. Their morphology, abundance
and function depends on species and developmental stage [1]. Some
well-known peroxisomal functions include fatty acid oxidation and
hydrogen peroxide detoxification, but many more exist [2]. Their im-
portance in human health is underlined by the severe diseases such as
adrenoleukodystrophy (ALD) caused by defects in peroxisome function
[3].
Peroxisome function is largely determined by peroxisomal protein
content. Most peroxisomal membrane proteins (PMPs) are synthesized
in the cytosol and targeted directly to peroxisomes [4] although a
subset of PMPs may be delivered to peroxisomes via the endoplasmic
reticulum [5]. PMPs regulate many aspects of peroxisome biology, in-
cluding peroxisomal protein import [6], peroxisome numbers [7] and
small molecule transport into peroxisomes [8]. For peroxisome
function, PMP homeostasis is vital; this includes the regulation of tar-
geting but also protein quality control processes and protein degrada-
tion. Recently, we demonstrated that the PMPs Pex3p and Pex13p in
the yeast Hansenula polymorpha are actively down-regulated [9,10].
Pex3p degradation initiates selective autophagy of peroxisomes while
Pex13p degradation is linked to peroxisomal matrix protein import.
Both Pex3p and Pex13p are degraded by the Ubiquitin Proteasome
System (UPS) [11]. In this system, ubiquitin (Ub) is activated by a
ubiquitin-activating enzyme (E1), then transferred to the active site
cysteine of an ubiquitin-conjugating enzyme (E2) and finally, Ub is
attached to the substrate with the aid of an ubiquitin ligase (E3)
[12–14]. Three classes of E3s exist. HECT E3 ligases accept Ub onto an
active site cysteine and then transfer Ub to a substrate [15,16], whereas
RING E3 ligases act as bridge between E2 and substrate, allowing Ub
transfer to occur [17,18]. The third class of E3 ligase, known as RING-
in-between-RING (RBR) E3s, contain a RING domain, followed by an
RBR domain and finally a RING-like domain [19]. These RBR E3s, like
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HECT E3s, accept Ub from an E2 onto a cysteine in the RING-like do-
main before transferring it to the substrate [20].
The examples of Pex3p and Pex13p demonstrate that targeted
down-regulation of PMPs does occur. However, because peroxisomes
are involved in various oxidative metabolic reactions, they can generate
large amounts of reactive oxygen species (ROS) such as hydrogen per-
oxide [21]. Because ROS are toxic compounds which cause damage to
biomolecules [22], it is highly likely that PMPs residing in the ROS rich
environment of the peroxisome undergo oxidative damage. Therefore,
PMP quality control is likely to play a vital role in peroxisome biology
yet to date little is known on how misfolded, non-functional or faulty
PMPs are targeted for degradation via quality control. Here we have
investigated PMP quality control in the yeast Saccharomyces cerevisiae
using Pxa1p as substrate. Pxa1p is a half-ABC transporter, containing
six transmembrane helices and a nucleotide-binding domain (NBD).
The hetero-dimerization of Pxa1p with Pxa2p, another half-ABC
transporter, is required for transporting acyl-CoA such as Oleoyl-CoA
into peroxisomes [23,24]. Pxa1p is the homologue of human adreno-
leukodystrophy protein (ALDP) [25]. Mutations in ALDP cause ALD
[26] and many ALDP mutants are rapidly degraded, likely by the pro-
teasome [27]. This has led to the suggestion that blocking ALDP
degradation might constitute a feasible therapeutic approach to treat
ALD [27,28]. However, to date little is known about the mechanisms
underlying ALDP instability or degradation.
Using a mutant form of Pxa1p (Pxa1MUT) that mimics ALD-causing
ALDP mutations, fused to mGFP, we show that Pxa1MUT-mGFP is ra-
pidly degraded from peroxisomes. Furthermore, we show that Pxa1MUT-
mGFP degradation is dependent on the proteasome while our data also
demonstrate a role for the E3 ligase Ufd4p in Pxa1MUT-mGFP de-
gradation. Finally, we show that inhibiting Pxa1MUT-GFP degradation
partially restores Pxa1p function in vivo. Taken together, our study
demonstrates that faulty PMPs can undergo proteasome-mediated de-
gradation. Furthermore, our observations on Pxa1MUT-mGFP degrada-
tion may provide new insights into the role of ALDP stability in ALD.
2. Results
2.1. Pxa1MUT-mGFP undergoes proteasome-mediated degradation from
peroxisomes
Unlike wild-type (WT) ALDP, many mutant versions of ALDP are




























































































Fig. 1. Pxa1MUT-mGFP targets to peroxisomes but displays reduced protein levels.
A Pxa1-mGFP and Pxa1MUT-mGFP localization in cells co-expressing Pex3-mKate2 (row 4 and 6). Cells pre-cultivated on glucose were grown on oleate/glucose media
to an OD600 of 1.5 and fluorescence images were taken. Here, a WT strain lacking fluorescent markers (row 1) together with WT strains expressing only Pex3-mKate2
(row 2), Pxa1-mGFP (row 3) or Pxa1MUT-mGFP (row 5) act as controls. Blue arrows- GFP spots, yellow arrows- mKate2 spots and red arrows- background fluor-
escence. The line profiles (taken from the spots indicated with blue or yellow lines in images of WT.Pxa1-mGFP + Pex3-mKate2 and Pxa1MUT-mGFP + Pex3-mKate2
cells) indicate normalized fluorescent intensity along a line drawn through the peroxisomes (dotted yellow line). Scale bar: 3 μm.
B Cells expressing Pxa1-mGFP or Pxa1MUT-mGFP were grown on oleate/glucose media to an OD600 of 1.5, lysed and samples were subjected to SDS-PAGE and
immunoblotting with antibodies against mGFP and Pyc.
C Bar chart displaying Pxa1-mGFP and Pxa1MUT-mGFP levels, normalized to the loading control Pyc. Protein levels in Pxa1-mGFP cells were set to 1. Values represent
the mean ± SD of three independent experiments. Here, asterisks represent statistically significant decrease in Pxa1MUT-mGFP levels compared to Pxa1-mGFP levels.
For quantification, blots in Fig. S1C were used. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.)
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control of faulty peroxisomal fatty acid transporters occurs. To in-
vestigate this in S. cerevisiae, we chose to study the degradation of the
yeast ALDP homologue Pxa1p. For this, we selected two ALD causing
mutations in ALDP, a commonly occurring glycine to serine substitution
at position 512 (p.Gly512Ser) together with a lysine to arginine sub-
stitution at position 513 (p.Lys513Arg), both present in the walker A
motif of the NBD (www.adrenoleukodystrophy.info). The p.Gly512Ser
mutation causes reduced protein stability in vivo [31] although im-
portantly, it does not abolish ATP-hydrolysis activity in vitro [32]. The
p.Lys513Arg mutation also causes protein instability in vivo (www.
adrenoleukodystrophy.info). The corresponding ALDP mutations
(p.Gly650Ser and p.Lys651Arg) were both introduced into yeast PXA1.
We chose to introduce two mutations to maximize the destabilizing
effect to Pxa1p. The Gly650Ser/Lys651Arg mutant form of Pxa1p is
referred to as Pxa1MUT. We choose to fuse Pxa1MUT to mGFP (Pxa1MUT-
mGFP), which allowed us to follow Pxa1MUT using both biochemical
and microscopy based techniques. Furthermore, the DNA encoding for
Pxa1MUT-mGFP was integrated into the genome of the S. cerevisiae
strains used and therefore represents the only copy of PXA1 in the cells.
Since Pxa1p functions in transporting fatty acyl-CoA, such as
Oleoyl-CoA, into peroxisomes for β-oxidation [23,24], we performed all
our experiments using cells grown on oleate containing media, to better
understand the turnover of Pxa1MUT-mGFP under conditions when the
protein is required. For this purpose, S. cerevisiae cells were pre-culti-
vated on glucose medium and shifted to oleate medium, to induce the
expression of the proteins required for peroxisomal β-oxidation
[33–35]. However, because we performed experiments using deletion
mutants that are unable to utilize oleate as carbon source (see below),
we used oleate medium containing 0.1% glucose throughout the study,
to allow results to be comparable. Therefore unless otherwise stated,
oleate medium always contained 0.1% glucose.
First, we investigated whether Pxa1MUT-mGFP is properly targeted
to peroxisomes. For this, we used fluorescence microscopy to examine
the localization of Pxa1MUT-mGFP in cells grown on oleate. Pex3-
mKate2 (Fig. 1A) or DsRed-SKL (Fig. S1A) was used as a marker for
peroxisomes. As control, we used cells producing an mGFP-tagged
version of WT Pxa1p (Pxa1-mGFP). We observed that mGFP spots co-
localized with mKate2 spots in strains expressing Pxa1-mGFP (Fig. 1A,
row 4) or Pxa1MUT-mGFP (Fig. 1A, row 6) while line profile data in-
dicate a strong correlation between the normalized fluorescent intensity
of mGFP and mKate2 (Fig. 1A, row 4 and row 6, right), indicating that
both Pxa1-fusions correctly target to peroxisomes. Likewise, mGFP
spots co-localized with DsRed spots in cells expressing Pxa1MUT-mGFP
and DsRed-SKL (Fig. S1A), confirming that Pxa1MUT-mGFP correctly
targets to peroxisomes. We also observed larger, more diffuse spots in
both mGFP and mKate2 channels (Fig. 1A, red arrows). However, these
were also seen in WT cells lacking fluorescent markers (Fig. 1A, row 1)
and likely represent auto-fluorescence.
The mGFP signal in cells expressing Pxa1MUT-mGFP was lower and
fewer GFP spots were visible compared to those expressing Pxa1-mGFP
(Fig. 1A, row 6), which is consistent with the reduced protein levels of
Pxa1MUT-mGFP compared to those of Pxa1-mGFP (Figs. 1B, C and S1C).
Lower protein levels could suggest either reduction in protein produc-
tion or reduced protein stability. To examine the stability of Pxa1MUT-
mGFP we performed chase analysis using the protein synthesis inhibitor
cycloheximide (CHX). For this purpose, cells were pre-cultivated on
glucose, transferred to oleate containing media (peroxisome inducing
conditions) and grown for 11 h until an OD600 of ~1.5. After 11 h of
growth in oleate containing media, cells were treated with either CHX
or DMSO (control), cells were grown further for 6 h (Pxa1-mGFP) or 2 h
(Pxa1MUT-mGFP) on inducing medium and samples were collected for
western blotting.
We observed an increase in Pxa1-mGFP and Pxa1MUT-mGFP levels
in DMSO-treated cells over time (Fig. 2A, DMSO), consistent with the
observation that Pxa1-mGFP levels continue to increase until ~36 h
after transfer of cells to induction medium (Fig. S1D). Significantly,
Pxa1MUT-mGFP was rapidly degraded and displayed a significantly
shorter half-life (~15 min) compared to Pxa1-mGFP (~360 min or 6 h)
(Fig. 2A, CHX and S1E) in cells treated with CHX, indicating that the
mutations introduced into Pxa1p result in protein instability.
Next, we sought to determine whether Pxa1MUT-mGFP degradation
occurs after targeting to peroxisomes. For this, we imaged CHX treated
WT cells co-expressing Pex3-mKate2 and Pxa1-mGFP or Pxa1MUT-
mGFP. We observed that the number of mGFP positive spots reduced
over time in cells expressing Pxa1MUT-mGFP (Fig. 2B, right panel) while
cells expressing Pxa1-mGFP displayed many more mGFP positive spots
after 120 min of CHX treatment (Fig. 2B, left panel). The number of
mKate2 spots remained stable after CHX treatment in both strains
(Fig. 2B). These observations suggest that Pxa1MUT-mGFP is degraded
from peroxisomes. To validate this further, we quantified mGFP and
mKate2 fluorescence intensities on peroxisomes in our fluorescent
images. We observed that, as expected, the mKate2 intensity remained
stable over time in the two strains (Fig. 2C). Likewise, the mGFP in-
tensity on peroxisomes in CHX-treated Pxa1-mGFP cells remained
stable (Fig. 2C, left panel) but decreased rapidly in Pxa1MUT-mGFP cells
treated with CHX (Fig. 2C, right panel). In addition, the mGFP/mKate2
ratio in CHX treated Pxa1MUT-mGFP cells decreased rapidly over time
but remained stable in Pxa1-mGFP cells after CHX addition (Fig. 2D).
The rate of the decrease in mGFP intensity in Pxa1MUT-mGFP cells
treated with CHX appears different from that obtained using western
blotting (Fig. 2A), likely due to the high background observed in the
mGFP channel (Fig. 1A, row 1 and 2). Together, these data strongly
suggest that Pxa1MUT-mGFP is rapidly degraded from peroxisomes.
Since ALDP mutants are thought to be degraded via the proteasome
[30], we first examined whether the proteasome has a role in Pxa1MUT-
mGFP degradation, through the use of a mixture of the proteasome
inhibitors MG132 and Bortezomib (Figs. 3A and S1F). We assessed
Pxa1MUT-mGFP turnover in cells lacking Pdr5p (the major drug efflux
transporter [36]), to enhance the uptake of inhibitors [37,38]. In ad-
dition, we examined Pxa1MUT-mGFP degradation in cells lacking
Atg12p (Figs. 3B and S1G), which is involved in autophagy [39]. From
our CHX chase analysis, we observed that Pxa1MUT-mGFP degradation
is inhibited in pdr5 cells after the addition of proteasome inhibitors
(Fig. 3A, CHX+ MG132 + Bortezomib) compared to non-treated cells
(Fig. 3A, CHX). These data, together with the observation that the de-
letion of ATG12 had no effect on Pxa1MUT-mGFP turnover (Figs. 3B and
S1G) demonstrates that the proteasome is involved in Pxa1MUT-mGFP
degradation. Next, we checked whether ubiquitination has a role in
Pxa1MUT-mGFP degradation by expressing a mutant form of ubiquitin
(UbK48R) in Pxa1MUT-mGFP cells, to inhibit poly-ubiquitin chain for-
mation on the substrate and subsequent degradation by the proteasome
[40]. We observed that Pxa1MUT-mGFP turnover is reduced in cells
expressing UbK48R, compared to Ub expressing cells (Figs. 3C and S1G).
However, we were unable to detect ubiquitinated Pxa1MUT-mGFP
(Fig. 3D). Possibly ubiquitinated Pxa1MUT-mGFP is below the level of
detection because of the high speed by which Pxa1MUT-mGFP is de-
graded. In summary, these data demonstrate that Pxa1MUT-mGFP un-
dergoes rapid, proteasome-mediated degradation from peroxisomes.
2.2. Identifying components required for Pxa1-tFT degradation
To gain the first insights into mechanisms of Pxa1MUT-mGFP quality
control, we set out to identify components required for Pxa1MUT-mGFP
degradation using a tandem fluorescent protein timer (tFT). A tFT is a
fusion of two fluorescent proteins; the slow maturing mCherry and the
rapid maturing sfGFP (Fig. 4A). When tagged to a protein of interest,
the mCherry/sfGFP ratio provides information on protein stability. tFT
fusions undergoing fast turnover are degraded prior to mCherry ma-
turation, resulting in a low mCherry/sfGFP ratio, whereas the mCherry/
sfGFP ratio increases for proteins with slower turnover [41]. Similar to
Pxa1MUT-mGFP, Pxa1-tFT levels in cells were much lower compared to
Pxa1-mGFP levels (Fig. 4B) while Pxa1-tFT was rapidly degraded in
S. Devarajan, et al. BBA - Biomembranes 1862 (2020) 183342
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cells treated with CHX (Figs. 4C and S1H). The turnover of tFT-tagged
Pex11p, a stable PMP [9], was slower in comparison (Figs. 4C and S1H).
Furthermore, the GFP immunoreactive band at around 33 kDa observed
with samples containing Pxa1-tFT (Figs. 4B and S1H, marked **) is
derived from incomplete tFT processing by the proteasome [42], sug-
gesting a role for the proteasome in Pxa1-tFT turnover. From these data,
we conclude that, similar to Pxa1MUT-mGFP, Pxa1-tFT undergoes pro-
teasome-mediated degradation and for this reason, we did not create a
Pxa1-tFT fusion containing the Gly650Ser/Lys651Arg mutations.
Next, we investigated the stability of Pxa1-tFT in a library of 132
strains that lack a protein involved in protein degradation or which
contained a mutant version of a protein involved in protein degradation
(in case the deletion was lethal) using a synthetic genetic array [43,44].
This library represents a large fraction of the factors known to have a
role in the degradation of proteins in yeast (see Table S2 for details on
which strains were included in the library). The effect of the mutations
on the stability of Pxa1-tFT was examined using mCherry/sfGFP in-
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days of growth on oleate/glucose plates. These mCherry/sfGFP ratios
were used to calculate a heat map of Z-scores (Fig. 4D), which depicts
the stability of Pxa1-tFT in each strain. A strain displaying similar Pxa1-
tFT stability as in WT cells would have a Z-score of 0 while strains with
enhanced stability would exhibit a Z-score > 0 (see Materials and
methods). Mutant strains that displayed an increase in Z-score > 1.0 on
two of the three days tested were considered as potential candidates
that increased Pxa1-tFT stability. Pxa1-tFT stability was increased in
cells lacking functional proteasomes (pre2, pre6, rpn10, rpt6-25 and
ubp6 cells) but not in cells lacking Atg12p (Fig. 4D), confirming a role
for the proteasome in Pxa1-tFT stability. These results demonstrate that
our tFT analysis is a valid way to identify factors potentially involved in
Pxa1MUT-mGFP degradation.
Pxa1-tFT stability was increased in strains deleted for genes coding
for the peroxisomal E2 Pex4p or one of the three peroxisomal E3 ligases
Pex2p, Pex10p and Pex12p [45] (Fig. 4D). Consistent with this, Pxa1-
tFT protein levels were enhanced in pex2 and pex4 cells (Fig. 4E),
thereby confirming our tFT data. Roles for these proteins in PMP ubi-
quitination/degradation have already been reported [9,10,46], sug-
gesting that common mechanisms may govern PMP ubiquitination and
degradation. However, Pxa1-tFT stability was also enhanced in cells
lacking a number of de-ubiquitinating enzymes (DUBs), which could
suggest a role for these DUBs in the deubiquitination of Pxa1MUT-mGFP
prior to proteasomal degradation. In addition, cells lacking the E3s
Nam7p, Dma2p, Tul1p and Ufd4p, the E3 co-factor proteins Ela1p and
Skp2p and the ubiquitin-binding protein Dsk2p (Supplementary Table
S2), factors not previously associated with peroxisomes, also displayed
enhanced Pxa1-tFT stability. Overall, our tFT analysis identified factors
potentially involved in the degradation of faulty Pxa1p.
2.3. Components involved in Pxa1-tFT stability play a role in Pxa1MUT-
mGFP degradation
Previously we demonstrated that the peroxisomal ubiquitination
machinery is required for the degradation of the PMPs Pex3p and
Pex13p [9,10]. Because deletion of PEX4, PEX2, PEX10 or PEX12 results
in Pxa1-tFT stabilization (Fig. 4D and E), we were interested to in-
vestigate whether they also had a role in Pxa1MUT-mGFP degradation.
Indeed, Pxa1MUT-mGFP levels were enhanced in cells deleted for PEX2
or PEX4 (Figs. 5A and S2A) while Pxa1MUT-mGFP turnover was also
inhibited in these cells (Figs. 5B and S2B), validating our tFT data as
well as indicating a role for these peroxisomal proteins in Pxa1MUT-
mGFP degradation. Furthermore, Pxa1MUT-mGFP localized to peroxi-
somes in these strains (Fig. 5C), indicating that stabilization did not
arise from mistargeting to other cell compartments. However, because
cells deleted for PEX2 or PEX4 also lack functional peroxisomes [47],
we investigated the impact of peroxisome function alone on Pxa1MUT-
mGFP turnover by assessing the stability and turnover of Pxa1MUT-
mGFP in pex5 cells, which also lack functional peroxisomes [48]. Our
data demonstrate that Pxa1MUT-mGFP degradation was inhibited in
pex5 cells (Figs. 5A, B and S2B), suggesting that Pxa1MUT-mGFP de-
gradation may be linked to peroxisome function. Again, Pxa1MUT-mGFP
targeting was not impaired in pex5 cells (Fig. 5C). We observed that
Pex3-mKate2 levels are comparable in WT, pex2, pex4 and pex5 cells
(Fig. S2C), suggesting that the effect of these deletion strains is not
general for all PMPs. Nevertheless, these data indicate that studying
Pxa1MUT-mGFP turnover in strains deficient in peroxisome function
could be challenging because any effects may potentially be indirect.
Therefore, we turned to investigate the role of candidates identified
in our tFT analysis not previously associated with peroxisome function,
including Ufd4p, Nam7p, Ela1p, Dsk2p, Skp2p, Tul1p and Dma2p.
Interestingly, we observed that Pxa1MUT-mGFP levels were significantly
higher in cells lacking Ufd4p (Figs. 6A and S2A). Deletion of ELA1,
DSK2, SKP2, TUL1 or DMA2 did not impact significantly on Pxa1MUT-
mGFP levels (Figs. 6A and S2A) and were not investigated further.
Furthermore, Pxa1MUT-mGFP levels were significantly lower in the
NAM7 deletion strain compared to the WT (Figs. 6A and S2A). How-
ever, because we were specifically interested in UPS mutants that in-
creased the stability of Pxa1MUT-mGFP, the role of NAM7 in Pxa1MUT-
mGFP stability was not investigated further.
Significantly, we observed that ufd4 cells retain the ability to grow
on media containing oleate as sole carbon source (Fig. 6B), indicating
that they contain functional peroxisomes and hence that Pxa1MUT-
mGFP stabilization in this strain does not stem from a deficiency in
peroxisome function. Since Ufd4p is a cytosolic E3 ligase that regulates
the degradation of faulty proteins [49], but it has not been linked to
peroxisome function, we chose to investigate the role of Ufd4p in
Pxa1MUT-mGFP degradation further. We performed CHX chase analysis
and observed that Pxa1MUT-mGFP degradation is inhibited in ufd4 cells
compared to WT cells (Figs. 6C and S2B). Furthermore, using fluores-
cence microscopy in combination with CHX chase assays, we in-
vestigated the localization and turnover of Pxa1MUT-mGFP in ufd4 cells.
As can be seen in Fig. 6D (t = 0, left panel), mGFP spots co-localize
with mKate2 spots in ufd4 cells. In addition, line profile data indicate
strong correlation between the normalized fluorescent intensity of
mGFP and mKate2, demonstrating that Pxa1MUT-mGFP is indeed loca-
lized to peroxisomes in ufd4 cells (Fig. 6D). The peroxisomal localisa-
tion of Pxa1MUT-mGFP in ufd4 cells was confirmed using DsRed-SKL as a
peroxisomal marker (Fig. S1A). Significantly, cells deleted for UFD4
display increased numbers of mGFP spots after 120 min of CHX treat-
ment, compared to the WT strain (Fig. 6D, right panel; t = 120 min).
Furthermore, mGFP spots in ufd4 cells co-localize with mKate2 spots
after 120 min of CHX treatment (Fig. 6D, left panel), demonstrating that
Pxa1MUT-mGFP accumulates on peroxisomes in these cells. Together,
these data establish that the E3 ligase Ufd4p is involved in the pro-
teasome-dependent degradation of Pxa1MUT-mGFP.
Fig. 2. Pxa1MUT-mGFP is rapidly degraded from peroxisomes.
A Cycloheximide (CHX) chase analysis on cells expressing Pxa1-mGFP and Pxa1MUT-mGFP. (Left) Cells pre-cultivated on glucose media were grown on oleate/glucose
media (inducing condition) to an OD600 of 1.5. After treatment with DMSO (Ctrl) or CHX, cells were grown further on inducing medium and samples were collected at
the indicated time points for immunoblotting with antibodies against mGFP and Pyc. (Right) Quantification of Pxa1-mGFP and Pxa1MUT-mGFP levels after CHX
addition. Protein levels were normalized to Pyc at the corresponding time point and to the protein levels at time point 0 (set to 1). Values represent the mean ± SD
of three independent experiments. For quantification, blots in Fig. S1E were used.
B Co-localization analysis of Pxa1-mGFP (Left) and Pxa1MUT-mGFP (Right) with the peroxisomal marker Pex3-mKate2 after CHX treatment. Cells expressing Pxa1-
mGFP or Pxa1MUT-mGFP together with Pex3-mKate2 were grown on oleate/glucose media to an OD600 of 1.5 and treated with CHX. Fluorescence images were taken
from cells grown on oleate/glucose media at the indicated time points (min) after CHX addition. Blue arrows- GFP spots, yellow arrows- mKate2 spots and red arrows-
background fluorescence. Scale bar: 3 μm. Line profiles were generated as described in Fig. 1.
C Box plot quantification of mGFP and mKate2 fluorescence intensity at the peroxisomal membrane in WT cells producing Pex3-mKate2 and Pxa1-mGFP (Left) or
Pxa1MUT-mGFP (Right) after CHX treatment. Fluorescence intensities were measured in cells (n = 40) using ImageJ as described in the materials and methods
section. The box represents intensity values from the 25th percentile to the 75th percentile. The orange area represents intensity values from the 25th -50th percentile
and the grey area represents intensity values from the 50th -75th percentile. Whiskers indicate maximum and minimum values.
D Average ratio ± SD per cell (n = 40) of mGFP to mKate intensities in WT cells producing Pex3-mKate2 and Pxa1-mGFP (Left) or Pxa1MUT-mGFP (Right). Numbers
above the columns (Left) depict the p-value. Asterisks (Right) denote significance between ratios at different time points, ** P < 0.01- statistically significant (Right)
and P > 0.05- not significant (Left). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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2.4. Inhibiting Pxa1MUT-mGFP degradation enhances peroxisomal β-
oxidation
Around 70% of the mutant forms of ALDP are unstable and are
degraded [30,50]. However, many of these mutants retain a certain
level of functionality [32]. This has led to the hypothesis that blocking
ALDP degradation could enhance ALDP activity in cells and be bene-
ficial for ALD patients [27–29]. Our data clearly indicate that Pxa1MUT-
mGFP builds up at peroxisomes when its degradation is inhibited in
ufd4 cells. Hence, we reasoned that we could use our experimental
setup as proof of principle and measured the capacity of WT and ufd4
cells expressing Pxa1-mGFP or Pxa1MUT-mGFP to perform β-oxidation
(Fig. 7A). Pxa1MUT-mGFP in WT cells displayed reduced activity in
comparison to Pxa1-mGFP (Fig. 7A) although higher than pxa1 cells,
indicating that importantly, Pxa1MUT-mGFP retains a degree of
functionality. Significantly, ufd4 cells expressing Pxa1MUT-mGFP ex-
hibited an increase in β-oxidation activity of around 15% compared to
the activity of WT.Pxa1MUT-mGFP cells (Fig. 7A). We also observed that
β-oxidation appeared enhanced in ufd4 cells expressing Pxa1-mGFP
compared to WT cells, although statistical analysis suggested that this
increase was not significant (Fig. 7A). To investigate further, we de-
termined the levels of Pxa1-mGFP in WT and ufd4 cells expressing
Pxa1-mGFP (Fig. 7B), observing that these levels were indeed increased
in ufd4 cells. Significantly, Pex14p levels were not affected by ufd4
deletion (Fig. 7B), indicating that the effect is likely to be specific for
Pxa1-mGFP.
Overall, our results provide proof of principle that blocking
Pxa1MUT-mGFP degradation can partially restore Pxa1MUT-mGFP func-
tion in cells, supporting the view that inhibiting ALDP degradation may
























































































































Fig. 3. Inhibiting the proteasome but not autophagy disturbs Pxa1MUT-mGFP degradation
A Graph representing Pxa1MUT-mGFP levels in pdr5 cells under proteasome inhibitor (PI) conditions. pdr5 cells expressing Pxa1MUT-mGFP pre-cultivated on glucose
were grown on oleate/glucose media for 10 h. After incubation with DMSO or proteasome inhibitors (MG132 and Bortezomib) for 90 min, CHX was added to DMSO
(represented as CHX) and PI treated cells (denoted as CHX + MG132 + Bortezomib). TCA samples for western blotting were collected from cells grown on oleate/
glucose media at the indicated time points after treatment with inhibitors. Protein levels were normalized to Pyc at the corresponding time point and to the protein
levels at time point 0 (set to 1). Values represent the mean ± SD of three independent experiments. For quantification, blots in Fig. S1F were used.
B Pxa1MUT-mGFP levels in WT and atg12 cells after CHX treatment. Cells pre-cultivated on glucose were grown on oleate/glucose media to an OD600 of 1.5 and
treated with CHX. TCA samples were collected from cells grown on oleate/glucose at the indicated time points after CHX treatment and probed with western blotting.
Protein levels were normalized to Pyc at the corresponding time point and to the protein levels at time point 0 (set to 1). For quantification, blots in Fig. S1G were
used.
C Quantification of Pxa1MUT-mGFP levels in WT cells and cells expressing Myc-tagged ubiquitin (Ub) or ubiquitin mutant (UbK48R) after treatment with CHX. The
experiment and quantification of levels were performed as mentioned in Fig. 3B. Values represent the mean ± SD of three independent experiments. For quan-
tification, blots in Fig. S1G were used.
D Immunoprecipitation performed using anti-GFP antibodies on lysates from pdr5 cells, pdr5.Pxa1MUT-mGFP cells, pdr5.Pxa1MUT-mGFP/MycUb cells and pdr5.MycUb
cells. Cells were pre-cultivated on glucose, transferred to oleate/glucose media for 10 h and incubated with proteasome inhibitors (MG132 and Bortezomib) for
90 min. Pxa1MUT-mGFP was immunoprecipitated under native conditions using GFP-trap magnetic beads. Load and elute fractions were subjected to immunoblotting
with antibodies against the Myc-tag (to detect Myc-ubiquitin) or the GFP-tag (to detect Pxa1MUT-mGFP).
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3. Discussion
Here we have demonstrated that a faulty version of the peroxisomal
fatty acid transporter Pxa1p is targeted for proteasome-dependent de-
gradation. Pxa1MUT-mGFP, our chosen substrate, is rapidly degraded
from peroxisomes. An important question remains how Pxa1MUT-mGFP
is recognized for degradation? The mutations introduced into Pxa1p
(Gly650Ser/Lys651Arg) are present in the conserved walker A motif of
the NBD [51]. Mutation of either these conserved lysine or glycine re-
sidues compromises both the ATP hydrolysis and substrate transloca-
tion activity of ABC transporters [52–54], including ALDP [32]. Hence,
the substitutions we introduced into Pxa1MUT-mGFP likely reduce ATP
hydrolysis and hence transport activity, which in turn could allow
Pxa1MUT-mGFP to be recognized for degradation. However, Pxa1p
forms a heterodimer with Pxa2p and deletion of PXA2 decreases the
stability of Pxa1p [55], indicating that Pxa2p binding is required for
Pxa1p stability. Therefore, it is equally possible that the substitutions in
Pxa1MUT-mGFP inhibit binding to Pxa2p, which in turn allows Pxa1MUT-
mGFP to be recognized for degradation. Interestingly, Byeon et al. re-
ported that mutating the walker A lysine in muscle adenylate kinase
results in a conformational change in the NBD [52] while recent work
on the bacterial transporter MJ0796 demonstrated that walker A lysine
mutations impact on both ATP hydrolysis and homo-dimerization [54].
Hence, we speculate that the introduced mutations in Pxa1MUT-mGFP
result in a conformational change in Pxa1p, which could allow the
protein to be recognized for degradation. Identifying which factors are
involved in the recognition of faulty peroxisomal fatty acid transporters
will provide valuable insights into the mechanisms underlying their
degradation.
Our data show that the addition of proteasome inhibitors sig-
nificantly reduce Pxa1MUT-mGFP turnover, demonstrating a role for the
proteasome in Pxa1MUT-mGFP degradation (Fig. 3A). While the data on
the ubiquitin mutant (UbK48) suggests that ubiquitination is involved in
Pxa1MUT-mGFP degradation (Fig. 3C), our attempts to detect ubiquiti-
nated forms of Pxa1MUT-mGFP proved unsuccessful (Fig. 3D). Notably,
ubiquitinated forms of ALDP carrying the R617H or H667D mutations
could also not be detected [30], even though these mutants were likely
degraded by the proteasome. There could be two possible explanations
for his: Pxa1MUT-mGFP is ubiquitinated but that the ubiquitinated form
of Pxa1MUT-mGFP is below the limit of detection, or that the ubiquiti-
nation of another protein could facilitate the degradation of Pxa1MUT-
mGFP. The latter mode of degradation has been proposed for several
substrates of the proteasome. Dang et al., reported that instead of A3G,
its binding partner viral infectivity factor (Vif) undergoes poly-ubiqui-
tination and this could be critical for A3G proteasomal degradation
[56], proposing that poly-ubiquitinated Vif might act as an adaptor
protein to bring A3G to the proteasome for degradation [57]. Another
protein that may be degraded via a similar mechanism is the retino-
blastoma tumour suppressor protein (Rb) [58]. Rb is thought to be
targeted for proteasomal degradation by the ubiquitination of its
binding partner, human papillomavirus protein E7 [58,59]. Pxa2p
forms a heterodimer with Pxa1p [23,24], but we do not suspect that
Pxa2p ubiquitination is required for Pxa1MUT-mGFP degradation be-
cause loss of Pxa2p does not inhibit Pxa1p degradation but instead
decreases the stability of Pxa1p [55]. Clearly further work is required to
investigate how ubiquitin contributes to the proteasome-mediated de-
gradation of Pxa1MUT-mGFP.
Based on the results of our tFT screening, several proteins not pre-
viously associated with peroxisomal function were identified that could
play a role in Pxa1-tFT stability (Fig. 4C). Of these, only loss of Ufd4p, a
cytosolic E3 ligase involved in the degradation of faulty proteins [49],
significantly increased the stability of Pxa1MUT-mGFP (Fig. 6A), in-
dicating that Ufd4p is involved in Pxa1MUT-mGFP degradation. Al-
though future work needs to investigate the mechanisms by which
Ufd4p controls Pxa1MUT-mGFP degradation, we consider it significant
that a cytosolic E3 ligase could regulate the turnover of a faulty PMP
because this indicates that general cellular quality control pathways can
facilitate the degradation of faulty PMPs. While the data we present
here concern the degradation of a mutant form of Pxa1p, we consider it
unlikely that the sole purpose of PMP quality control is the degradation
of mutant PMPs; we consider it more likely that damaged PMPs un-
dergo quality control. As previously mentioned, the ROS rich environ-
ment of the peroxisome could result in the oxidative damage of pro-
teins, which could suggest that damaged Pxa1p undergoes PMP quality
control. In line with this, although Pxa1-mGFP is much more stable
than Pxa1MUT-mGFP in our CHX experiments, degradation of Pxa1-
mGFP does occur (Fig. 2A) while Pxa1-mGFP levels are higher in ufd4
cells compared to WT cells (Fig. 7B). Therefore, it is plausible that
Pxa1MUT-mGFP is targeted for degradation via quality control me-
chanisms that usually acts upon damaged Pxa1p because Pxa1MUT-
mGFP is impaired in function.
Deletion of UFD4 does not fully inhibit the degradation of Pxa1MUT-
mGFP. Similarly, Pxa1MUT-mGFP degradation appears only partly re-
duced in cells lacking the peroxisomal E3 ligase Pex2p. This could
suggest that two pathways target Pxa1MUT-mGFP for degradation, one
requiring Ufd4p and the other involving Pex2p or perhaps that Pex2p
and Ufd4p collaborate to facilitate Pxa1MUT-mGFP degradation. Ufd4p
can team up with Ubr1p, a RING E3, to facilitate the degradation of
Mgt1p, a DNA repair demethylase [60]. However, the impact of per-
oxisome function on Pxa1MUT-mGFP degradation remains to be de-
termined, meaning that further data on the role of Pex2p (and other
members of the peroxisomal ubiquitination machinery) are required to
Fig. 4. Identifying factors involved in Pxa1MUT-tFT degradation by tandem fluorescent timer.
A Schematic representation of the Pxa1-tandem fluorescent timer (tFT) fusion. Pxa1p is fused to two fluorescent proteins with different maturation kinetics: rapidly
maturing sfGFP and slow maturing mCherry. The fluorescent intensity ratio of mCherry to sfGFP provides information of Pxa1p stability.
B WT cells together with cells expressing Pxa1-mGFP, Pxa1-tFT or Pxa1MUT-mGFP were initially grown on glucose, shifted to oleate/glucose media and grown until
an OD600 of 1.5. After lysis, samples were probed by immunoblotting with antibodies against mGFP and Pyc. *denotes a shorter, mCherry-sfGFP product resulting
from mCherry hydrolysis during TCA treatment [42,81] and ** denotes a tFT fragment produced by incomplete proteasomal processing [42].
C The stability of tFT tagged Pxa1p and Pex11p was assayed using CHX chase analysis. Cells pre-cultivated on glucose were grown on oleate/glucose media an
OD600−1.5. After treatment with CHX, cells were further grown on oleate/glucose media and samples collected at the indicated points were subjected for western
blotting. Protein levels obtained at each time point were normalized to Pyc at the corresponding time point and to the protein levels at time point 0 (set to 1). Values
represent the mean ± SD of three independent experiments. For quantification, blots in Fig. S1H were used.
D Screen for components involved in Pxa1-tFT stability. WT and mutant cells expressing Pxa1-tFT were grown on oleate/glucose plates and fluorescent intensities
were measured. The resulting mCherry/sfGFP ratio on the indicated days (1–3) were used to calculate the Z-score (see materials and methods). Z-score colour coded
from blue (decrease) to red (increase), represents changes in Pxa1-tFT stability. Mutant strains with Z-score > 1.0 (indicated by *) on two of the three days tested
were defined as potentially interesting.
E Western blot analysis of Pxa1-tFT levels in WT, atg12, pex2 and pex4 cells grown on oleate/glucose media to an OD600 of 1.5. After lysis, samples were probed by
immunoblotting with antibodies against mGFP and Pyc. *denotes a shorter, mCherry-sfGFP product resulting from mCherry hydrolysis during TCA lysate preparation
[42]. The apparent discrepancy between the molecular weight of Pxa1-tFT in this panel and in Fig. 4B is because samples here were run onto a 7.5% acrylamide SDS-
PAGE gel while samples in 4B were loaded onto a 10% acrylamide SDS-PAGE gel, resulting in a different run profile. (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
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validate this hypothesis. Nevertheless, a model that depicts Pex2p and
Ufd4p teaming up to degrade faulty PMPs remains an attractive one.
Mutations in gene sequences can result in formation of faulty pro-
teins, which could pose serious threats to the cell, for two reasons. One
reason is the loss of protein activity. However, there is also gain-of-toxic
function that is unrelated to the protein's function and which has be-
come increasingly relevant to human disease [61]. Faulty proteins often
expose hydrophobic regions normally buried within the core [62] that
may take part in unwanted protein-protein interactions, resulting in
protein aggregation [63]. To minimize such harmful effects, cell em-
ploys protein quality control systems to remove faulty proteins [64].
For instance, mutations at position F508 in Cystic fibrosis transmem-
brane conductance regulator (CFTR), which increase the tendency of
CFTR to aggregate but do not inhibit activity completely [65,66], result
in rapid protein degraded [67]. However, the rapid degradation of






















































































































Fig. 5. Pxa1MUT-mGFP degradation is inhibited in peroxisome deficient strains.
A Bar chart displaying Pxa1MUT-mGFP levels in WT, pex2 and pex4 strains (Left) and WT, atg12 and pex5 strains (Right). Cells pre-cultivated on glucose were grown
on oleate/glucose to an OD600 of ~1.5 and TCA samples were collected for western blotting. For quantification of Pxa1MUT-mGFP levels, blots in Fig. S2A were used.
Pxa1MUT-mGFP levels in WT were set to 1, values represent the mean ± SD of three independent experiments. Asterisks represent statistically significant increase of
Pxa1MUT-mGFP levels in mutant strains compared to in WT cells. ** P < 0.01- statistically significant and P > 0.05- not significant (NS).
B CHX chase of Pxa1MUT-mGFP in WT, pex2 and pex4 strains (Top) and WT, atg12 and pex5 strains (Bottom). Cells were grown on oleate/glucose media to an OD600 of
1.5, treated with CHX and samples were collected from oleate/glucose grown cells at the indicated time points after CHX treatment. Protein levels were normalized to
Pyc at the corresponding time point and to the protein levels at time point 0 (set to 1). Values represent the mean ± SD of three independent experiments. For
quantification, blots in Fig. S2B were used.
C Co-localization analysis of Pxa1MUT-mGFP with the peroxisomal marker Pex3-mKate2 in WT, pex2, pex4 and pex5 cells. The WT strain lacking fluorescent markers
was used as control. Fluorescence images were taken from cells grown on oleate/glucose media to an OD600 of 1.5. Blue arrows- GFP spots, yellow arrows- mKate2
spots and red arrows- background fluorescence. Scale bar: 3 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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resulting in the severe condition cystic fibrosis [68] and several lines of
research have focused on blocking CFTR degradation as potential
treatment for cystic fibrosis [69]. Similarly, many ALDP mutant pro-
teins that cause ALD are unstable, leading to the suggestion that
blocking ALDP degradation could represent a novel treatment for ALD
[27]. Indeed, a subset of ALDP mutant proteins in patient cells become
stable under low-temperature culture conditions and exhibit proper
peroxisomal localization [27] while they also display increased residual
β-oxidation activity [28]. Though unstable, a significant proportion of
ALDP mutants retain a certain degree of function [27,32]. In line with
this, our data demonstrate that Pxa1MUT-mGFP cells display increased
β-oxidation compared to pxa1 cells (Fig. 7A), indicating that Pxa1MUT-
mGFP is partly functional. Furthermore, stabilizing Pxa1MUT-mGFP,
through the deletion of UFD4, enhances peroxisomal β-oxidation in
cells, which would indeed support the notion that blocking ALDP mu-
tant degradation might constitute a feasible therapeutic approach to
treat ALD. However, Yamada et al. indicated that proteasome inhibitors
enhance the stability of certain ALDP mutants but did not increase
peroxisomal β-oxidation in the corresponding cells [29]. While these









































































































































































































Fig. 6. Ufd4, a cytosolic E3 ligase is involved in Pxa1MUT-mGFP degradation.
A Pxa1MUT-mGFP levels in WT, ufd4, nam7, ela1, dsk2, skp1, tul1 or dma2 cells. TCA samples for western blotting were collected from cells pre-cultivated on glucose
and grown on oleate/glucose to an OD600 of ~1.5. For quantification of Pxa1MUT-mGFP levels, blots in Fig. S2A were used. Pxa1MUT-mGFP levels in WT were set to 1,
values represent the mean ± SD of three independent experiments. Numbers above the columns depict the p-value.
B Ten-fold serial dilutions of WT and pex4 cells together with WT and ufd4 cells producing Pxa1MUT- mGFP were spotted on oleate plates and grown at 30 °C for
7 days.
C CHX chase of Pxa1MUT-mGFP in WT and ufd4 strains. Cells were pre-cultivated on glucose, grown on oleate/glucose to an OD600 1.5, treated with CHX and samples
were collected from oleate/glucose grown cells at the indicated time points after CHX addition. Protein levels were normalized to Pyc at the corresponding time point
and to the protein levels at time point 0 (set to 1). Values represent the mean ± SD of three independent experiments. For quantification, blots in Fig. S2B were used.
D Co-localization analysis of Pxa1MUT-mGFP with the peroxisomal marker Pex3-mKate2 in ufd4 (Top panel) or WT (Bottom panel, taken from Fig. 2A, for com-
parison) cells, after CHX treatment. Cells were grown as indicated in Fig. 6C and images were taken from cells grown on oleate/glucose media at the indicated time
points (min) after CHX treatment. Blue arrows- GFP spots, yellow arrows- mKate2 spots and red arrows- background fluorescence, Scale bar: 3 μm. Line profiles were
generated as described in Fig. 1. The circular structures visible in GFP images of ufd4.Pxa1MUT-mGFP cells (top panel) expressing Pxa1MUT-mGFP can also be seen in
images of WT.Pxa1MUT-mGFP cells (Fig. S1B, top lane) and likely represent large peroxisomes. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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note that the location where the mutants build up upon stabilization is
critical in determining whether stabilization will result in enhanced
activity. Yamada and co-workers did not address this in their study [29]
and it is possible that these ALDP mutants are stabilized elsewhere in
the cell. Hence, further work on the mechanism of ALDP degradation is
therefore needed to understand at which point blocking ALDP mutant
degradation could positively affect ALDP activity. Nevertheless, our
data demonstrate that UFD4 deletion results in a build-up of Pxa1MUT-
mGFP at the peroxisomal membrane and significantly, a human
homologue of Ufd4p, known as TRIP12 [70], is involved in the de-
gradation of a range of different proteins [71–73]. It would therefore be
interesting to investigate whether TRIP12 has a role in ALDP de-
gradation and if so, whether blocking TRIP12 dependent ALDP mutant
degradation improves β-oxidation in ALD patients.
In summary, we have demonstrated that a faulty peroxisomal fatty
acid transporter undergoes proteasome-mediated degradation and
identify Ufd4p as playing an important role in facilitating this de-
gradation. In addition, these results may help to shed new light on the
role of ALDP degradation in ALD.
4. Materials and methods
4.1. Construction of plasmids and S. cerevisiae strains
S. cerevisiae transformations were performed with the Lithium
acetate method, as described previously [74]. S. cerevisiae strains and
plasmids used in this study are listed in Tables 1 and 2 respectively. The
primers used in the study are listed in Table S1. Phusion DNA poly-
merase (Thermo Scientific) was used for the amplification of gene
fragments.
The S. cerevisiae WT.Pxa1-mGFP strain was constructed as follows.
PCR was performed on pHIPZ-mGFP using the Pxa1-mGFP Fw and
Pxa1-mGFP Rev. primers to amplify the C-terminal region of PXA1 to-
gether with the Zeocin resistance cassette (bleMX6) and the mGFP
coding sequences and the obtained PCR fragment was transformed into
the yMaM330 strain. The plasmid pGW053 was constructed as follows:
the genomic region of the PXA1 gene was amplified by PCR using
Forward primer VIP1080, 485 bp upstream of open reading frame and
Reverse primer VIP1081, 192 bp downstream of ORF. This was inserted
into Ycplac111 using gap repair between EcoR1 and HindIII sites, re-
sulting in pGW046. This plasmid was used as template for site directed
mutagenesis to generate Pxa1 G650S/K651R using VIP672 and VIP673,
producing pGW053. For the construction of S. cerevisiae WT.Pxa1MUT-
mGFP, first a recombinant plasmid pHIPZ-Pxa1MUT-mGFP was con-
structed. PCR was performed on pGW053 using Pxa1MUT Fw and
Pxa1MUT Rev. primers to amplify the C-terminal region of PXA1 (car-
rying the two mutations G650S/K651R) and to introduce Pcil and BglII
sites. The resulting DNA fragment, digested with Pcil and BglII, was
cloned into Pcil/BglII cut pHIPZ-mGFP to generate pHIPZ-Pxa1MUT-
mGFP. PCR was then performed on pHIPZ-Pxa1MUT-mGFP using
Int_Pxa1MUT Fw and Int_Pxa1MUT Rev. to amplify the Pxa1MUT-mGFP
fragment and the obtained PCR product was then transformed into the
yMaM330 strain. The obtained PCR fragment was also transformed into
pdr5, atg12 and ufd4 strains to pdr5.Pxa1MUT-mGFP, atg12.Pxa1MUT-
mGFP and ufd4.Pxa1MUT-mGFP respectively. The positive transfor-
mants of WT.Pxa1MUT-mGFP, pdr5.Pxa1MUT-mGFP, atg12.Pxa1MUT-
mGFP and ufd4.Pxa1MUT-mGFP were checked both by colony PCR and
sequencing. In addition, PCR fragment was also transformed into nam7,
ela1, dsk2, skp2, dma2 and tul1 cells to generate the mutant strains
expressing Pxa1MUT-mGFP.
The S. cerevisiae Pxa1-tFT strain was generated as follows. PCR was
performed on pMaM168 to amplify C-terminal region of PXA1 and tFT
tagging module using primers Pxa1-tFT Fw and Pxa1-tFT Rev. The
generated PCR product was then transformed into yMaM330. Strains
expressing Pex3-mKate2 were constructed as follows. Pex3-mKate2
cassette consisting of C-terminal region of PEX3, hygromycin resistance
gene (hphMX) and mKate2 coding sequences was amplified from
pHIPH-Pex14mKate2 using primers Pex3-mKate Fw and Pex3-mKate
A





































































Fig. 7. Inhibiting Pxa1MUT-mGFP degradation enhances β-oxidation activity in vivo.
A Bar chart displaying β-oxidation activity in WT and ufd4 cells expressing Pxa1-mGFP or Pxa1MUT-mGFP. β-oxidation activity was measured in cells grown overnight
on oleate/glucose media. β-oxidation in pxa1 and fox1 cells acts as control. The activity in WT.Pxa1-mGFP cells was taken as a reference [100%]. Values represent
the mean ± SD of four independent experiments. Numbers above the columns depict the p-value calculated to determine whether changes to β–oxidation activity in
the different strains, are significant.
B Bar chart displaying Pxa1-mGFP and Pxa1MUT-mGFP levels in WT and ufd4 cells. Pex14p levels in WT and ufd4 cells acts as a control. Cells pre-cultivated on glucose
were grown on oleate/glucose to an OD600 of 1.5, cells were lysed and samples were probed by immunoblotting. For quantification, blots in Fig. S2C were used. Pxa1-
mGFP levels in WT.Pxa1-mGFP cells were set to 1. Similarly, Pex14 levels in WT.Pxa1-mGFP cells were used as a reference and set to 1. Values represent the
mean ± SD of three independent experiments. Numbers above the columns depict the p-value calculated to determine whether changes to Pxa1/Pxa1MUT-mGFP or
Pex14p levels in the different strains, when compared to the corresponding WT strain, are significant.
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Rev. The generated PCR fragment was transformed into WT, WT.Pxa1-
mGFP, WT.Pxa1MUT-mGFP and ufd4.Pxa1MUT-mGFP. Furthermore, the
PCR fragment was also transformed into pex2. Pxa1MUT-mGFP, pex4.
Pxa1MUT-mGFP and pex5. Pxa1MUT-mGFP strains, which were gener-
ated as described below.
S. cerevisiae WT.Pxa1MUT-mGFP and ufd4.Pxa1MUT-mGFP strains
expressing DsRed-SKL were constructed as follows. First, the PCR cas-
sette (consisting of TEF promoter and DsRed-SKL coding sequences) was
digested NotI/SalI and cloned into NotI/SalI cut pHIPX7-DsRed-SKL to
create pHIPH7-DsRed-SKL. The PCR cassette containing TDH3 pro-
moter sequence was amplified from pPTDH3-GFP-SKL was digested with
NotI/BamHI and cloned into NotI/BamHI cut pHIPH7-DsRed-SKL, to
create pHIPH8-DsRed-SKL. The resulting plasmid after linearization
with MunI was transformed into WT.Pxa1MUT-mGFP and ufd4.Pxa1MUT-
mGFP strains to generate WT.Pxa1MUT-mGFP. DsRedSKL and
ufd4.Pxa1MUT-mGFP. DsRed-SKL respectively. In these strains, the ex-
pression of DsRed-SKL was under the control of TDH3 promoter.
S. cerevisiae WT.Pxa1MUT-mGFP+MycUb and WT.Pxa1MUT-mGFP
+MycUbK48R strains were constructed as follows. First, the Yeast
episomal plasmids (YEP) expressing MycUb and MycUbK48R from the
CUP1 promoter were constructed: the CUP1 promoter coding sequence
was amplified from pCGCN-FAA4 using primers CUP1_Fw and
CUP1_Rev, digested with NotI/BamHI and cloned into NotI/BamHI cut
pRDV1 (MycUb) or pRDV2 (MycUbK48R). The resulting vectors were
then used to amplify Pcup1-MycUb and Pcup1-MycUbK48R sequences
individually using primers CUP1_Fw and MycUb/UbK48R_Rev and
these PCR fragments were digested with NotI and SacI and cloned into
NotI/SacI cut pRG226 (Addgene, 64529). The YEP-PCUP1-MycUbK48R
plasmid was transformed into the WT.Pxa1MUT-mGFP strain to generate
WT.Pxa1MUT-mGFP+MycUbK48R. The YEP-PCUP1-MycUb plasmid was
Table 1
Yeast strains used in this study.
Strain Description [genotype] Reference
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 [82] (Knop lab)
BJ1991 MATa, leu2, trp1, ura3-251, prb1-1122, pep4-3, gal2 [80]
yMaM330 [Wild type- WT] MATalpha his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 can1Δ:: STE2pr-spHIS5 lyp1Δ::STE3pr-LEU2
leu2Δ::GAL1pr- I-SCEI-natNT2
[82] (Knop lab)
WT.PEX3-mKate2 yMaM330, PEX3::mKate2-hphMX This study (Fig. 1)
WT.PXA1-mGFP yMaM330, PXA1::mGFP-bleMX6 This study (Figs. 1, 2, 4, 7, S1 and
S2)
WT.PXA1MUT-mGFP yMaM330, PXA1G650S/K651R::mGFP-bleMX6 This study (Figs. 1, 2, 3, 4, 5, 6, 7,
S1 and S2)
WT. PXA1MUT-mGFP + PEX3-mKate2 yMaM330, WT. PXA1MUT-mGFP + PEX3::mKate2-hphMX This study (Fig. 1)
WT. PXA1-mGFP + PEX3-mKate2 yMaM330, WT. PXA1-mGFP + PEX3::mKate2-hphMX This study (Fig. 1 and Fig. 2)
WT. PXA1MUT-mGFP + DsRed-SKL yMaM330, WT. PXA1MUT-mGFP + SKL::DsRed-hphMX This study (Fig. S1)
PXA1-tFT yMaM330, PXA1::mCherry-I-SceIsite-SpCYC1term-ScURA3-I-SceIsite-mCherryΔN-sfGFP This study (Figs. 4 and S1H)
PEX11-tFT yMaM330, PEX11::mCherry-I-SceIsite-SpCYC1term-ScURA3-I-SceIsite-mCherryΔN-sfGFP Knop lab (Figs. 4 and S1H)
UPS deletion library BY4741, goi deletions::kanMX [82]
yMaM344 yMaM330, ura3Δ0::mCherry∆N-I-SceIsite-SpCYC1term-ScURA3-I-SceIsite-mCherry∆N [82]
atg12 atg12 deletion strain, BY4741, atg12::kanMX Knop lab
pex2 pex2 deletion strain, BY4741, pex2::kanMX Knop lab
pex4 pex4 deletion strain, BY4741, pex4::kanMX Knop lab
ufd4 ufd4 deletion strain, BY4741, ufd4::kanMX Knop lab
pdr5 pdr5 deletion strain, BY4741, pdr5::kanMX Knop lab
nam7 nam7 deletion strain, BY4741, nam7::kanMX Knop lab
ela1 ela1 deletion strain, BY4741, ela1::kanMX Knop lab
dsk2 dsk2 deletion strain, BY4741, dsk2::kanMX Knop lab
skp2 skp2 deletion strain, BY4741, skp2::kanMX Knop lab
dma2 dma2 deletion strain, BY4741, dma2::kanMX Knop lab
tul1 tul1 deletion strain, BY4741, tul1::kanMX Knop lab
atg12.PXA1-tFT yMaM330, PXA1-tFT + atg12::kanMX This study (Fig. 4)
pex2.PXA1-tFT yMaM330, PXA1-tFT + pex2::kanMX This study (Fig. 4)
pex4.PXA1-tFT yMaM330, PXA1-tFT + pex4::kanMX This study (Fig. 4)
pdr5.PXA1MUT-mGFP BY4741, pdr5 + PXA1G650S/K651R:: mGFP-bleMX6 This study (Figs. 2 and S1)
atg12.PXA1MUT-mGFP BY4741, atg12 + PXA1G650S/K651R:: mGFP-bleMX6 This study (Figs. 2, 4, S1 and S2)
pex2.PXA1MUT-mGFP YMaM330, WT. PXA1MUT-mGFP + pex2 deletion pex2::kanMX This study (Figs. 5 and S2)
pex2.PXA1MUT-mGFP + PEX3-mKate2 yMaM330, pex2 PXA1MUT-mGFP + PEX3::mKate2-hphMX This study (Fig. 5)
pex4.PXA1MUT-mGFP YMaM330, WT. PXA1MUT-mGFP + pex4 deletion pex4::kanMX This study (Figs. 5 and S2)
pex4.PXA1MUT-mGFP + PEX3-mKate2 yMaM330, pex4 PXA1MUT-mGFP + PEX3::mKate2-hphMX This study (Fig. 5)
pex5.PXA1MUT-mGFP YMaM330, WT. PXA1MUT-mGFP + pex5 deletion pex5::kanMX This study (Figs. 5 and S2)
pex5.PXA1MUT-mGFP + PEX3-mKate2 yMaM330, pex5 PXA1MUT-mGFP + PEX3::mKate2-hphMX This study (Fig. 5)
ufd4.PXA1MUT-mGFP BY4741, ufd4 + PXA1G650S/K651R::mGFP-bleMX6 This study (Figs. 6, 7 and S2)
ufd4.PXA1MUT-mGFP + PEX3-mKate2 ufd4 PXA1MUT-mGFP + PEX3::mKate2-hphMX This study (Fig. 6)
nam7.PXA1MUT-mGFP BY4741, nam7 + PXA1G650S/K651R::mGFP-bleMX6 This study (Fig. 6)
ela1.PXA1MUT-mGFP BY4741, ela1 + PXA1G650S/K651R::mGFP-bleMX6 This study (Fig. 6)
dsk2.PXA1MUT-mGFP BY4741, dsk2 + PXA1G650S/K651R::mGFP-bleMX6 This study (Fig. 6)
skp2.PXA1MUT-mGFP BY4741, skp2 + PXA1G650S/K651R::mGFP-bleMX6 This study (Fig. 6)
dma2.PXA1MUT-mGFP BY4741, dma2 + PXA1G650S/K651R::mGFP-bleMX6 This study (Fig. 6)
tul1.PXA1MUT-mGFP BY4741, tul1 + PXA1G650S/K651R::mGFP-bleMX6 This study (Fig. 6)
ufd4.PXA1MUT-mGFP + DsRed-SKL ufd4 PXA1MUT-mGFP + SKL::DsRed-hphMX This study (Fig. S1)
ufd4.PXA1-mGFP BY4741, ufd4 + PXA1::mGFP-bleMX6 This study (Figs. 7 and S2)
fox1 BJ1991, fox1::kanMX
pxa1 yMaM330, pxa1 deletion, pxa1::hphMX This study (Fig. 7)
WT.PXA1MUT-mGFP+MycUbK48R yMaM330, WT PXA1MUT-mGFP + PCUP1-MycUbK48R [yeast episomal plasmid, YEP-Pcup1-
MycUbK48R]
This study (Figs. 3 and S1)
WT.PXA1MUT-mGFP+ MycUb WT PXA1MUT-mGFP + PCUP1-MycUb [yeast episomal plasmid, YEP-Pcup1-MycUb] This study (Figs. 3 and S1)
pdr5+ MycUb pdr5 + [yeast episomal plasmid, YEP-Pcup1-MycUb] This study (Figs. 2 and S1)
pdr5.PXA1MUT-mGFP + MycUb pdr5.PXA1MUT-mGFP +[yeast episomal plasmid, YEP-Pcup1-MycUb] This study (Figs. 2 and S1)
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transformed individually into WT.Pxa1MUT-mGFP, pdr5.Pxa1MUT-mGFP
and pdr5 strains to generate WT.Pxa1MUT-mGFP+MycUb,
pdr5.Pxa1MUT-mGFP + MycUb and pdr5 + MycUb respectively.
4.2. Construction of S. cerevisiae deletion strains
The pxa1 deletion strain was constructed by replacing the PXA1
region with the hygromycin resistance gene (hphMX). A PCR fragment
containing the hygromycin resistance gene and PXA1 flanking regions
were amplified from pHIPH-Pex14mKate2 using primers DPxa1_Fw and
DPxa1_Rev. The resulting PXA1 deletion cassette was transformed into
yMaM330. For the construction of pex5.Pxa1MUT-mGFP, the PEX5 de-
letion cassette (geneticin resistance gene and PEX5 flanking regions)
amplified from pFa6AkanMX6 using primers DPex5_Fw and DPex5_Rev
was transformed in WT.Pxa1MUT-mGFP.
S. cerevisiae pex2 and pex4 strains expressing Pxa1MUT-mGFP or
Pxa1-tFT were constructed as follows. The pex2 and pex4 deletion
cassettes consisting of geneticin resistance cassette (kanMX) and PEX2
or PEX4 flanking regions were amplified from pFa6AkanMX6 using
DPex2_Fw and DPex2_Rev (for PEX2 deletion cassette) and DPex4_Fw
and DPex4_Rev (for PEX4 deletion cassette). The obtained deletion
cassettes were then transformed individually into WT.Pxa1MUT-mGFP
and Pxa1-tFT strains to generate pex2. Pxa1MUT-mGFP, pex4. Pxa1MUT-
mGFP, pex2.Pxa1-tFT and pex4.Pxa1-tFT strains.
For the construction of atg12.Pxa1-tFT strain, deletion cassette
consisting of geneticin resistance cassette (kanMX) and ATG12 flanking
regions was amplified from pFa6AkanMX6 using primers DAtg12_Fw
and DAtg12_Rev (for ATG12 deletion cassette). The obtained deletion
cassette was then transformed into Pxa1-tFT to generate atg12.Pxa1-tFT
strain.
All gene integrations were confirmed by colony PCR using Phire Hot
Start II DNA polymerase (Thermo Fisher Scientific) and gene deletions
were checked by colony PCR as well as southern blotting analysis of
chromosomal DNA, using the ECL Direct Nucleic Acid Labelling and
Detection system (Thermo Fisher Scientific), according to the protocol
provided by the manufacturer.
4.3. Growth conditions
The Escherichia coli strain DH5α was used for cloning purposes. E.
coli cells were grown in LB supplemented with 100 μg/mL Ampicillin at
37 °C. Yeast transformants were selected on YPD plates containing 2%
agar and 100 μg/mL Zeocin (Invitrogen), 150 μg/mL Geneticin
(Invitrogen) or 300 μg/mL Hygromycin (Invitrogen) or on YND plates
containing 6.7 g/L yeast nitrogen base without amino acids (YNB,
Difco), 5 g/L D- glucose monohydrate (Sigma-Aldrich), 2% agar and
30 mg/L Leucine, 20 mg/L Histidine and 20 mg/L Methionine or
30 mg/L Uracil, when required.
For all the experiments, yeast cells were initially cultured at 30 °C
on YM2 medium (6.7 g/L YNB, 1% casein hydrolysate (Sigma-Aldrich),
60 mg/L uracil, 60 mg/L tryptophan) containing either 2% or 0.3% (w/
v) glucose. To induce peroxisome proliferation, cells grown on YM2
medium plus 0.3% glucose were transferred to YNO-glucose medium
(6.7 g/L YNB, 1% casein hydrolysate, 60 mg/L uracil, 60 mg/L tryp-
tophan, 0.05% tween, 0.1% oleate and 0.1% glucose). For strains ex-
pressing Myc tagged ubiquitin: MycUb and MycUbK48R under the con-
trol of CUP1 promoter and uracil coding gene, URA3 (Table 1), cells
were pre-cultured at 30 °C on YM2 medium (lacking uracil) plus 0.3%
glucose and then grown on YNO-glucose medium (lacking uracil) to an
OD600 of 1.5. To inhibit protein synthesis, cells were treated with cy-
cloheximide (CHX, Sigma-Aldrich) to a final concentration of 6 mg/mL.
To inhibit proteasome, cells were treated with 70 μM of MG1232
(Sigma-Aldrich) and 70 μM of Bortezomib (Selleckchem).Where in-
dicated, an equal amount of DMSO (control for CHX) was added to
cells. For spot assays, yeast strains were grown overnight on YM2
medium containing 2% glucose and shifted to YM2 medium plus 0.3%
Table 2
Plasmids used in this study.
Plasmid Description Use Reference
pGW053 YCplac111 plasmid containing PXA1 carrying two mutations G650S/K651R;
LEU2, AmpR
Amplification of C-terminal PXA1 (with G650S/
K651R)
This study
pHIPZ-mGFP fusinator pHIPZ containing mGFP; bleMX6, AmpR 1. Vector for cloning [83]
2. C-terminal mGFP tagging to PXA1; genome
integration
pHIPZ-Pxa1MUT-mGFP pHIPZ- mGFP containing C-terminal PXA1with two mutations G650S/K651R
[PXA1MUT]; bleMX6, AmpR
C-terminal mGFP tagging to PXA1MUT; genome
integration
This study
pHIPH-Pex14mKate2 pHIPH containing mKate2 and C-terminal of PEX14; hphMX, AmpR 1. C-terminal mKate2 tagging to PEX3; genome
integration
[9]
2. Gene disruption (pxa1) by hphMX marker
pFA6a- kanMX6 pFA6a plasmid containing geneticin (kanMX6) resistance gene; kanMX, AmpR Gene disruption (atg12, pex2, pex4 and pex5) by
kanMX6 marker
[82]
pMaM168 pFA6a plasmid containing tFT module (mCherry-I-SceIsite-SpCYC1term-
ScURA3-I-SceIsite-mCherryΔN-sfGFP); URA3, AmpR
1. C-terminal tFT tagging; PXA1-tFT and PEX11-tFT
integration into yMaM330
[82]
pRG226 Yeast episomal plasmid (YEP); URA3, 2 μ ori Vector for cloning Addgene, 64529
pCGCN-FAA4 Plasmid containing CUP1 promoter and mGFP; bleMX6, AmpR Amplification of CUP1 promoter; cloning [83]
pRDV1 Plasmid containing Myc tagged ubiquitin (Ub) under control of DHAS
promoter; hphMX, AmpR
Amplification of MycUb; vector for cloning [10]
pRDV2 Plasmid containingMyc tagged ubiquitin mutant (UbK48R) under the control
of DHAS promoter; hphMX, AmpR
Amplification of MycUbK48R; Vector for cloning [10]
YEP-PCUP1-MycUb Yeast episomal plasmid (YEP) containing CUP1promoter and MycUb; URA3,
AmpR
Integration into WT. PXA1MUT-mGFP strain This study
YEP-PCUP1-MycUbK48R Yeast episomal plasmid (YEP) containing CUP1promoter and MycUbK48R;
URA3, AmpR
Integration into WT and WT. PXA1MUT-mGFP This study
pHIPX7-DsRedSKL Plasmid containing DsRed-SKL under the control of TEF promoter; LEU2,
AmpR
Vector for cloning [84]
pHIPH7-DsRed-SKL Plasmid containing DsRed-SKL under the control of TEF promoter; hphMX,
kanR
Vector for cloning This study
pPTDH3-GFP-SKL Plasmid containing GFP-SKL under the control of TDH3 promoter; LEU2,
AmpR
Amplification of TDH3 promoter; cloning [85]
pHIPH8-DsRedSKL Plasmid containing DsRed-SKL under the control of TDH3 promoter, hphMX
AmpR
Integration into WT. PXA1MUT-mGFP and ufd4.
PXA1MUT-mGFP strain
This study
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glucose. After 6 h of growth in YM2 plus 0.3 glucose, yeast cells were
spotted onto oleate plates containing 6.7 g/L YNB, 0.1% yeast extract,
0.1% oleate, 0.05% Tween, 2% agar and when required uracil (30 mg/
L), leucine (60 mg/L), methionine (20 mg/L) and histidine (20 mg/L)
was added. Plates were incubated at 30 °C for 7 days before imaging.
4.4. Preparation of yeast TCA lysates
Cell extracts of TCA-treated cells were prepared for SDS-PAGE as
described previously [75]. SDS-PAGE and western blotting were per-
formed by established methods. Equal volume of samples were loaded
per lane and blots were probed with antibodies against mGFP (Santa
Cruz Biotech, sc-9996), pyruvate carboxylase 1 (Pyc), Pex14p, rabbit
polyclonal antisera raised against the Myc tag (Santa Cruz Biotech, sc-
789) or HA tag (Sigma, H6908). Secondary goat anti-rabbit (Thermo
Fisher Scientific, 31460) or goat anti-mouse (Thermo Fisher Scientific,
31430) antibodies conjugated to horseradish peroxidase or alkaline
phosphatase were used for detection. Pyc was used as a loading control.
4.5. Quantification of Western blots
Western blots were scanned using a densitometer (Bio-Rad, GS-710)
and protein levels were quantified using Image J software (https://
imagej.nih.gov/ij/). The intensity of each band measured was nor-
malized by dividing by the intensity of the corresponding Pyc band
(loading control). The normalized Pxa1MUT-mGFP values were com-
pared to Pxa1-mGFP values, which was set to 1. The levels of Pxa1MUT-
mGFP in mutant cells are displayed relative to Pxa1MUT-mGFP levels in
WT (set to 1). For CHX experiments, the normalized values at time
point 0 (T0) was set to 1.0 and values obtained after CHX addition at
indicated time points are displayed as a fraction of T0 values. Standard
deviations were calculated using Excel. Significance was determined
using two tailed student's t-test. * represents P-values < 0.05, ** re-
presents P-values < 0.01, and *** represents P-values < 0.001. The
data presented are derived from three independent experiments.
4.6. tFT screening with UPS deletion library
Tandem fluorescent protein timers (tFT): mCherry and sfGFP were
endogenously tagged to Pxa1 as described [76]. By the use of a pinning
robot (Singer Instruments), Pxa1-tFT was crossed to UPS deletion li-
brary or an array of haploid strains consisting of knockout, temperature
sensitive (ts) and Decreased Abundance by mRNA perturbation (DAmp)
alleles of individual components of the Ubiquitin Proteasome System
(UPS) [44,77,78]. In addition, Pxa1-tFT was crossed to a control strain
expressing kanMX selection marker from the ura3Δ locus, referred to as
wild-type (WT). Screens were performed in 1536 format, with four
technical replicates of each cross arranged next to each other. The se-
lection of diploids, sporulation and the selection of haploids carrying
Pxa1-tFT and a genetic perturbation, was performed by sequential
pinning on appropriate selective media as described [79], followed by
seamless marker excision [76]. Using an Infinite M1000 Pro plate
reader equipped with automatic plate loading stacker (Tecan) and
custom temperature control chamber, mCherry intensity (587/10 nm
excitation, 610/10 nm emission) and sfGFP intensity (488/10 nm ex-
citation, 510/10 nm emission) was measured from colonies grown on a
modified YNO-glucose medium containing (6.7 g/L YNB, 2 g/L amino
acid dropout mix (-LEU), 0.05% tween, 0.1% oleate, 0.1% glucose and
2% agar). First set of measurements were taken after 24 h of growth and
measurements were taken every 24 h until 72 h (3 days).
Whole colony fluorescence intensities (mCherry and sfGFP), ob-
tained from UPS mutant crossed to Pxa1-tFT, were corrected for auto
fluorescence by subtracting the measurements of a corresponding mu-
tant crossed to the control strain, yMaM344 (expressing non-fluorescent
protein). The median value was calculated out of the four technical
replicates. The corrected values of mCherry divided by the sfGFP values
yielded a ratio, representing the stability of Pxa1-tFT in the UPS mu-
tants. Similarly, the mCherry/sfGFP ratio of Pxa1-tFT in WT was cor-
rected for auto fluorescence. Using the ratios obtained on day one, two
and three a Z- score for each day was calculated by the formula. A Z-
score indicates how many standard deviations a value is from the mean
of all values. Z-score can be calculated from the formula: Z = (X - μ)/σ.
In the formula, Z is the Z-score, X is the value of the element, μ is the
population mean, and σ is the standard deviation. A negative Z-score
indicates that the value of the element is below average while positive
Z-score indicates the value is above average. To identify UPS mutants
which potentially increased the stability of Pxa1-tFT, Z-score (Z) was
calculated using the formula.
= X µZ mCherry / sfGFP ratio in a UPS mutant( ) mean mCherry / sfGFP ratio in WT and UPS mutants( )
Standard deviation of mCherry / sfGFP ratio in WT and UPS mutants( )
A strain (UPS mutant) with a Z-score of 0 indicates that Pxa1-tFT sta-
bility is similar to the WT as well to the population mean (WT and UPS
mutants). While, the mutants with Z-score of 1.0 and 2.0 indicates that
the mCherry/sfGFP ratio in a corresponding mutant is different from
the WT and population mean by 1.0 and 2.0 standard deviations.
Hence, mutant stains displaying a Z-score > 0 indicate enhanced Pxa1-
tFT stability. UPS mutants with an increase in Z-score > 1.0 on two of
the three days tested were considered as potential candidates that sig-
nificantly increased Pxa1-tFT stability. The heat map generated using
the Z-scores (obtained from mCherry/sfGFP ratio of Pxa1-tFT in UPS
mutants and the WT) is presented in Fig. 2D.
4.7. Fluorescence microscopy
All images were captured at room temperature using an inverted
microscope (Axio Scope A1, 100 × 1.30 NA Plan-Neofluar objective,
Carl Zeiss), Micro-Manager software and a digital camera (CoolSNAP
HQ2; Photometrics). For wide field microscopy, GFP fluorescence was
visualized with a 470/440-nm band pass excitation filter, a 495-nm
dichromatic mirror, and 525/50-nm band pass emission filter. mCherry
fluorescence was visualized with a 587/25-nm band pass excitation
filter, a 605-nm dichromatic mirror, and 647/70-nm band pass emis-
sion filter.
For co-localization analysis, cells were pre-grown on YM2 medium
containing glucose, transferred to YNO-glucose (low fluorescence)
medium and grown until an OD600 of 1.5 after which fluorescence
microscopy images were captured. For CHX chase analysis, cells grown
in the same way as indicated above were treated with cycloheximide
(CHX) and images were taken from cells grown on oleate/glucose at
indicated time points (min) after CHX treatment (Fig. 2B). The acquired
images were processed using Image J software (https://imagej.nih.gov/
ij/) with optimal settings: mGFP (200, 500), mKate2 (200, 600) and
DsRed (200, 500). For co-localization analysis in WT, pex2, pex4 and
pex5 cells expressing Pxa1MUT-mGFP and Pex3-mKate2 (Fig. 5C),
images were processed using optimal settings: mGFP (200, 800) and
mKate2 (200, 600). For quantifying the co-localization of Pxa1-mGFP
or Pxa1MUT-mGFP in cells expressing peroxisomal markers (Pex3-
mKate2 or DsRed-SKL) (Figs. 1, 2, 6 and S1), a line was drawn along
GFP and mKate2/DsRed-SKL spots using ImageJ and the intensity was
measured. Using this data, normalized fluorescent intensity of green
and red spots were calculated and plotted against the distance of the
line (from the beginning to the end).
For quantification of the Pex3-mKate2 and Pxa1-mGFP or Pxa1MUT-
mGFP fluorescence intensities in CHX treated cells (Fig. 2C), a rectan-
gular area was drawn using ImageJ to envelope the region containing
the mGFP/mKate2 spot and pixel intensity inside the area was mea-
sured. Since the cells expressing Pxa1MUT-mGFP contain very few mGFP
positive spots at the later time points of CHX treatment, the rectangular
area selected contained the peroxisomal marker or Pex3-mKate2 spots
and the corresponding mGFP intensity was measured. The maximum
fluorescence intensity of mGFP measured on peroxisomes was corrected
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for the background intensity and a box plot was made using Microsoft
Excel. The box represents values from the 25 percentile to the 75 per-
centile; the horizontal line through the box represents the median
value. Whiskers indicate maximum and minimum values. The mKate2
intensity was calculated and displayed in a similar way (Fig. 2C). To
calculate the mGFP/mKate2 intensity ratio, the maximum intensity of
Pxa1-mGFP or Pxa1MUT-mGFP, obtained at different time points after
CHX treatment, was divided by the corresponding maximum intensity
of Pex3-mKate2 in each cell. The dataset was subjected to the two-tail t-
test. * represents P-values < 0.05, ** represents P-values < 0.01 and
*** represents P-values < 0.001.
4.8. Immunoprecipitation assay
Immunoprecipitation was performed on cells grown on YNO-glu-
cose medium for 10 h and incubated with proteasome inhibitors
(MG132 and Bortezomib) for 90 min. Around 14 OD units of each strain
were harvested by centrifugation. Immunoprecipitation using GFP-
Trap® _M beads was performed according to manufacturer's protocol
(Chromotek) with slight modifications. Cells were washed once with
1 mL cold lysis or RIPA buffer (50 mM Tris/Cl pH 7.5, 150 mM NaCl,
2 mM EDTA, 0.1% SDS, 1% Triton X-100 and 0.5% Deoxycholate) and
resuspended in 0.75 mL of lysis buffer containing 2.5 μg/mL leupeptin
and 1 mM PMSF (added just prior to use). Yeast cells were then lysed
using glass beads (~30 min) and samples were centrifuged at 8000 rpm
at 4 °C for 10 min to remove cellular debris and unbroken cells. A
fraction of supernatant (Load fraction) was collected and stored for
SDS-PAGE analysis. The remaining supernatant fractions were then
incubated with 30 μl GFP-Trap® _M beads (Chromotek) for 2 h at 4 °C
under constant mixing. The beads were magnetically separated until the
supernatant was clear. The supernatant was discarded and beads were
washed five times using 500 μl ice cold wash buffer (50 mM Tris/Cl
pH 7.5, 150 mM NaCl and 2 mM EDTA). The GFP-Trap® _M beads were
then resuspended in 60 μl 4× SDS-Sample buffer and boiled for 10 min
at 95 °C. Finally, the beads were separated magnetically and the su-
pernatant (Elute fraction) was collected. The load and elute fractions
were subjected to SDS-PAGE and immunoblotting with antibodies
against GFP and Myc tagged epitope.
4.9. β- Oxidation assay
Yeast strains were grown on glucose medium containing 5 g/L D
glucose, and 6.7 g/L YNB. When required; histidine, leucine, uracil, or
methionine was added. To induce peroxisome proliferation cells were
grown for at least 24 h on 5 g/L glucose medium, and then transferred
to YPO medium (1.07 g/L oleate, 2.16 g/L Tween-80, 5 g/L peptone,
3 g/L yeast extract, 25 mM potassium phosphate buffer (pH = 6)). Cells
were grown overnight in YPO medium to induce β-oxidation. β-
Oxidation assay in intact cells were performed as described previously
by [80] with slight modifications. The β-oxidation capacity was mea-
sured in 50 mM MES, pH 6.0 and 9 g/L NaCl supplemented with 10 μM
1-14C-oleate. Subsequently, 14C-CO2 was trapped with 2 M NaOH and
used to quantify the rate of fatty acid oxidation. Results are presented as
percentages relative to the rate of oxidation of wild-type cells expres-
sing Pxa1-mGFP (set to 100). The data presented are from four in-
dependent experiments and significance is calculated using two-tailed
student's t-test. * represents P-values < 0.05, ** represents P-values <
0.01, and *** represents P-values < 0.001.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbamem.2020.183342.
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